Wall Street Zen Upgrades Humacyte (NASDAQ:HUMA) to Sell

Humacyte (NASDAQ:HUMA) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

HUMA has been the subject of several other research reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Tuesday, April 28th. HC Wainwright upped their price target on shares of Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, July 8th. TD Cowen reduced their price objective on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a research note on Wednesday, June 17th. Finally, Benchmark boosted their target price on shares of Humacyte to $2.00 and gave the company a “speculative buy” rating in a report on Monday, June 1st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.25.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $0.65 on Friday. The company has a debt-to-equity ratio of 5.46, a current ratio of 3.93 and a quick ratio of 3.32. The stock has a market capitalization of $145.07 million, a PE ratio of -1.15 and a beta of 2.54. Humacyte has a one year low of $0.55 and a one year high of $2.76. The business’s fifty day moving average price is $0.90 and its 200-day moving average price is $0.93.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $1.46 million. On average, equities research analysts anticipate that Humacyte will post -0.34 EPS for the current year.

Insider Transactions at Humacyte

In related news, insider Shamik J. Parikh sold 45,887 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the completion of the transaction, the insider owned 272,713 shares of the company’s stock, valued at approximately $245,441.70. The trade was a 14.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius bought 56,818 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were purchased at an average cost of $0.88 per share, for a total transaction of $49,999.84. Following the acquisition, the director directly owned 148,025 shares in the company, valued at $130,262. This trade represents a 62.30% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. R Squared Ltd purchased a new position in shares of Humacyte during the 4th quarter valued at $25,000. Atom Investors LP purchased a new stake in shares of Humacyte in the fourth quarter worth $25,000. Prudential Financial Inc. purchased a new stake in shares of Humacyte in the second quarter worth $28,000. Financial Advisors Network Inc. bought a new stake in Humacyte during the second quarter valued at $28,000. Finally, Equitable Holdings Inc. bought a new stake in Humacyte during the third quarter valued at $29,000. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.